FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs.
about
Influence of immunoglobulin isotype on therapeutic antibody functionEngineered antibody Fc variant with selectively enhanced Fc RIIb binding over both Fc RIIaR131 and Fc RIIaH131Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies.Targeting the tumor microenvironment to enhance antitumor immune responsesInhibitory Fcγ receptor is required for the maintenance of tolerance through distinct mechanisms.bIgG time for large eaters: monocytes and macrophages as effector and target cells of antibody-mediated immune activation and repression.Regulation of Monoclonal Antibody Immunotherapy by FcγRIIB.Improving therapeutic activity of anti-CD20 antibody therapy through immunomodulation in lymphoid malignancies.The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking.Special Conference on Tumor Immunology and Immunotherapy: A New Chapter.Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinking.OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy.TNF-receptor superfamily agonists as molecular adjuvants for cancer vaccines.Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies.
P2860
Q26772080-8C145B3C-62CC-47A3-AD13-5216F9E30D86Q27678516-81DBCF33-5566-49E5-A51B-E980EE514E9FQ34978570-A99E5BC3-E680-4055-89F4-D743D2D9344CQ35176307-38300640-A9DC-447A-AB40-30850618C1EFQ38538598-F85C5BD6-F937-42E0-9F88-8D25C4D654E0Q38615353-837B1308-8785-4330-B8E1-4E3DA6907CA1Q38752906-F80887DF-B3D9-4BA1-B522-A3E88B959256Q38799409-DEC021C0-B3F1-41C5-AFAA-2D79AC425B83Q39674450-E8054A05-263A-4269-91EB-CB48FB2094FCQ40945758-419B7194-1270-40CB-84B7-40AABC395B85Q42729928-6FFE9267-387F-4E00-B207-E9B066192F76Q44805706-53046883-2746-47A1-951B-B50CF7FABF0FQ45064262-DED84938-43A9-49CD-A281-B2072438A22CQ47325431-D8E04476-E3DD-4151-A559-6271166314A1Q52342639-41B3B546-1374-4056-A52E-13E043111A12
P2860
FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs.
@en
type
label
FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs.
@en
prefLabel
FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs.
@en
P2093
P2860
P1476
FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs
@en
P2093
Ann L White
H T Claude Chan
Martin J Glennie
Ruth R French
Stephen A Beers
P2860
P2888
P304
P356
10.1007/S00262-013-1398-6
P577
2013-03-31T00:00:00Z
P5875
P6179
1022824791